Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.

Jiwon Koh^1,2, Koung Jin Suh³, Hye Yeon Park⁴, Hyun Jung Kwon⁵, Hyun-Jung Sung⁵, Han Suk Ryu^1,2, Jung Ho Kim¹, Jaemoon Koh¹, Kyung-Hun Lee^2,4, Dae-Won Lee^2,4, Changhee Park^2,4, Jeongmin Seo³, Heejung Chae³, Woochan Hwang⁶, Ye Yoon Suh⁶, Chang Ho Ahn⁶, Seock-Ah Im^2,4, Jee Hyun Kim³, So Yeon Park⁵

¹Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.

²Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.

³Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Gyeonggi, Republic of Korea.

⁴Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.

⁵Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Gyeonggi, Republic of Korea.

⁶Lunit Inc., Seoul, Republic of Korea.

PubMed DOI

Abstract

AIMS: To characterize the heterogeneity of pathological responses in the breast and regional lymph nodes after neoadjuvant pembrolizumab-based chemoimmunotherapy in early-stage triple-negative breast cancer (TNBC) and to explore their clinical implications. METHODS AND RESULTS: A total of 203 patients with TNBC treated with neoadjuvant chemotherapy combined with pembrolizumab followed by surgery…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.